Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Scancell soars as it confirms Cancer Research UK to fund and sponsor SCIB2 clinical trial

“We are delighted to announce this partnership with Cancer Research UK, which is a significant endorsement for our ImmunoBody technology”
race for life
Cancer Research UK is one of the world’s leading cancer charities

Shares in Scancell Holdings PLC (LON:SCLP) soared on Thursday morning after the company revealed Cancer Research UK is to fund and sponsor a Phase I/II clinical trial of its SCIB2 lung cancer vaccine.

Scancell said the tie-up was a “significant endorsement” of its ImmunoBody platform – the underlying technology behind both SCIB1 and SCIB2 which helps to prime a patient’s immune system to recognise and kill specific cancer cells.

Cancer Research to manage the trial

The study that Cancer Research UK – one of the world’s leading cancer charities – is to pay for will see patients with solid lung cancer tumours treated in combination with a checkpoint inhibitor.

The charity’s Centre for Drug Development will be responsible for manufacturing the clinical trial supplies of SCIB2, conducting the pre-clinical testing, as well as sponsoring and managing the trial itself.

Once the study has been completed, Scancell will have the option to acquire the rights to the data to support the further development of SCIB2 itself.

If Scancell decides not to do this, Cancer Research will retain the right to take the programme forward in all indications, not just lung cancer.

Scancell CSO “delighted”

“The charity's world-renowned expertise will no doubt be invaluable as we progress SCIB2 through the clinic,” said chief scientific officer Lindy Durrant.

“In pre-clinical studies, we have shown that a combination of SCIB2 and checkpoint inhibition produces enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

“We believe SCIB2 has the potential to provide a much needed treatment option for patients suffering from a range of common solid tumours.”

Shares jumped 14% to 14.3p on Thursday morning.

--Updates for share price--

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Related Articles

Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use